Asthma Clinical Trial
Official title:
Fluctuation of Airway Function in Children With Asthma Phenotype as a Predictor of Outcome
It is increasingly recognised that asthma is not a single disease but that there are many different phenotypes. Much of the work that we have previously carried out has focussed on differentiating children with difficult asthma (those whose asthma control improves with attention to the basics of asthma management such as adherence) from those with severe therapy resistant asthma (ongoing poor control despite high dose treatment and attention to the basics. Our collaborators in Basel, Switzerland have demonstrated that serial measurements of lung function (peak flow) in adults can characterise the severe asthma phenotype and its stability in adults with asthma. We plan to carry out twice daily peak flow measurement sin children with asthma using an electronic peak flow meter. We will analyse peak flow patterns in children with severe therapy resistant asthma (STRA), difficult asthma (DA) and mild to moderate asthma. We will also investigate the relationship between peak flow variations and symptoms, recorded in a daily diary and medication use, recorded by an electronic measuring device which attaches to the child's own inhaler (Smart-inhaler).
Many children present with poorly controlled asthma despite high intensity treatment
including high doses of inhaled steroids. A number of these children will get better once
the basics of asthma management are addressed (such as adherence, allergen avoidance,
smoking cessation). The remainder will need further escalation of treatment (with attendant
side effects) and more invasive, investigations. Adults with severe asthma have been found
to have differences in the fluctuation patterns of peak flow compared to mild asthmatics.
This study will enable us to evaluate whether the same is true in children, enabling us to
improve the way we identify children with difficult asthma (DA) and severe therapy resistant
asthma (STRA) and whether the difficult asthma: DA group are in fact more similar to the
mild/moderate group.
Asthma exacerbations are a serious and concerning problem in children with asthma. This
study will enable us to assess whether mathematical modelling of fluctuation patterns can
enable us to predict n asthma attack and therefore intervene before it becomes severe or
even life threatening. This study will also enable us to investigate the relationship
between symptoms, peak flow patterns, exacerbations and adherence to inhaled corticosteroids
(ICS) as measured by electronic recording devices (Smart-inhalers).
This is an observational cohort study. If the child and their family are happy to
participate in the study the first study visit can take place immediately. If they would
like time to consider the study it can be deferred until their next routine attendance at
the hospital.
Study visit 1:
Information will be collected relating to past medical history, asthma history and current
medications (this information may also be obtained from the case notes).
The following standardised questionnaires will be used: Asthma Control Test, children >12
years (ACT) or Childhood Asthma Control Test, children 6-11years (cACT) (usually completed
as part of a routine clinical visit); Mini Paediatric Asthma Quality of Life Questionnaire
(PAQLQ); Medicines Adherence Rating Scale (MARS); Beliefs about Medicines Questionnaire
(BMQ).
Study procedures:
Lung function (included as part of a routine clinic visit), bronchodilator reversibility
(lung function repeated after administration of salbutamol), exhaled nitric oxide.
The child and their family will be issued with a paper diary, electronic peak flow meter
(PIKO) and electronic monitoring device for their inhaler (Smart-inhaler) and shown how to
use these.
Between visits:
Children will be asked to measure their peak flow twice daily (morning and evening) and
record their symptoms in a diary. Their parents will also be asked to complete the diary.
They will be contacted by the study investigator to check whether there are any technical
problems and as a reminder to make the peak flow measurements and complete the diary.
Visit 2, approximately 12 weeks later (from 8 to 16 weeks)
The second study visit will be scheduled at the time of a planned hospital appointment. This
will largely be a repeat of visit 1:
Information will be collected relating to asthma control and exacerbations since visit 1.
The following standardised questionnaires will be used: Asthma Control Test, children >12
years (ACT) or Childhood Asthma Control Test, children 6-11years (cACT) (usually completed
as part of a routine clinical visit); Mini Paediatric Asthma Quality of Life Questionnaire
(PAQLQ)
Study procedures:
Lung function (included as part of a routine clinic visit), bronchodilator reversibility
(lung function repeated after administration of salbutamol), exhaled nitric oxide.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|